Showing results (31-40 of 50) with videos related to
Sort By:
Pageof 5
Alimentary Pharmacology & Therapeutics|June 1, 2019
The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosisAli Jibran Mecci, Polychronis Kemos, Clifford Leen, et al.Gastroenterology|December 31, 2003
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virusRobert Perrillo, Hie-Won Hann, David Mutimer, et al.Gut|August 3, 2010
Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver diseaseJulie Parkes, Paul Roderick, Scott Harris, et al.Hepatology International|April 13, 2011
Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistanceRobert P Perrillo, Hie-Won Hann, Eugene Schiff, et al.Journal of Viral Hepatitis|September 26, 2020
Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infectionPhilip J Johnson, Sarah Berhane, Alex J Walker, et al.The Journal of Infection|October 20, 2019
Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance GroupDaniel Bradshaw, Jean L Mbisa, Anna Maria Geretti, et al.Annals of Hepatology|May 29, 2016
Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis CXavier Forns, Samuel Didier, David Mutimer, et al.The Journal of Infectious Diseases|March 5, 2021
Real-World Outcomes of Direct-Acting Antiviral Treatment and Retreatment in United Kingdom-Based Patients Infected With Hepatitis C Virus Genotypes/Subtypes Endemic in AfricaElihu Aranday-Cortes, C Patrick McClure, Christopher Davis, et al.Hepatology (Baltimore, Md.)|May 13, 2011
Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological responseRoeland Zoutendijk, Jurriën G P Reijnders, Ashley Brown, et al.Journal of Hepatology|March 20, 2018
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosisMassimo Puoti, Graham R Foster, Stanley Wang, et al.Pageof 5